Aastrom Biosciences Inc Share Price Nasdaq
Equities
US00253U3059
Pharmaceuticals
End-of-day quote
Other stock markets
|
||
- USD | - |
08/05 | Vericel Q1 Loss Narrows, Revenue Increases; 2024 Outlook Lifted -- Shares Rise Pre-Bell | MT |
08/05 | Earnings Flash (VCEL) VERICEL CORPORATION Posts Q1 Revenue $51.3M, vs. Street Est of $49.1M | MT |
Sales 2024 * | 24Cr 2TCr | Sales 2025 * | 30Cr 2.5TCr | Capitalization | 233.77Cr 20TCr |
---|---|---|---|---|---|
Net income 2024 * | 40L 33Cr | Net income 2025 * | 2.4Cr 200.37Cr | EV / Sales 2024 * | 9.73 x |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 7.81 x |
P/E ratio 2024 * |
560
x | P/E ratio 2025 * |
103
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 99.07% |
Latest transcript on Aastrom Biosciences Inc
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 60 | 01/13/01 | |
Joseph Mara
DFI | Director of Finance/CFO | 49 | 25/21/25 |
Michael Halpin
COO | Chief Operating Officer | 62 | 10/17/10 |
Members of the board | Title | Age | Since |
---|---|---|---|
Paul Wotton
BRD | Director/Board Member | 63 | 06/15/06 |
Kevin McLaughlin
BRD | Director/Board Member | 67 | 06/15/06 |
Robert Zerbe
CHM | Chairman | 73 | 16/06/16 |
1st Jan change | Capi. | |
---|---|---|
-2.35% | 8.91TCr | |
+2.76% | 4.09TCr | |
-12.92% | 3.22TCr | |
+54.69% | 2.51TCr | |
-16.51% | 1.54TCr | |
-8.27% | 1.19TCr | |
-42.60% | 1.19TCr | |
-12.82% | 1.16TCr | |
+7.34% | 903.23Cr |